KR102499522B1 - 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체 - Google Patents

세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체 Download PDF

Info

Publication number
KR102499522B1
KR102499522B1 KR1020227017575A KR20227017575A KR102499522B1 KR 102499522 B1 KR102499522 B1 KR 102499522B1 KR 1020227017575 A KR1020227017575 A KR 1020227017575A KR 20227017575 A KR20227017575 A KR 20227017575A KR 102499522 B1 KR102499522 B1 KR 102499522B1
Authority
KR
South Korea
Prior art keywords
och
compound
delete delete
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227017575A
Other languages
English (en)
Korean (ko)
Other versions
KR20220080003A (ko
Inventor
마커스 피셔
파테메 케라마트니아
케빈 맥고완
재키 민
지젤 에이. 니시구치
지닌 프라이스
조란 랭코빅
다스 수라브
찰스 지. 멀리건
윤차오 창
Original Assignee
세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 filed Critical 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드
Publication of KR20220080003A publication Critical patent/KR20220080003A/ko
Application granted granted Critical
Publication of KR102499522B1 publication Critical patent/KR102499522B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227017575A 2020-09-23 2021-09-23 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체 Active KR102499522B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082365P 2020-09-23 2020-09-23
US63/082,365 2020-09-23
PCT/US2021/051648 WO2022066835A1 (en) 2020-09-23 2021-09-23 Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein

Publications (2)

Publication Number Publication Date
KR20220080003A KR20220080003A (ko) 2022-06-14
KR102499522B1 true KR102499522B1 (ko) 2023-02-13

Family

ID=80845797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017575A Active KR102499522B1 (ko) 2020-09-23 2021-09-23 세레브론 단백질의 조절제로서의 치환된 n-(2-(2,6-디옥소피페리딘-3-일)-1,3-디옥소이소인돌린-5-일)아릴설폰아미드 유사체

Country Status (14)

Country Link
US (2) US12454518B2 (cg-RX-API-DMAC10.html)
EP (1) EP4217352A4 (cg-RX-API-DMAC10.html)
JP (1) JP7856636B2 (cg-RX-API-DMAC10.html)
KR (1) KR102499522B1 (cg-RX-API-DMAC10.html)
CN (1) CN116209439B (cg-RX-API-DMAC10.html)
AU (1) AU2021347238A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023005344A2 (cg-RX-API-DMAC10.html)
CA (1) CA3196278A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023000394A1 (cg-RX-API-DMAC10.html)
IL (1) IL301588A (cg-RX-API-DMAC10.html)
MX (1) MX2023003114A (cg-RX-API-DMAC10.html)
PE (1) PE20230847A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022066835A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202304644B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
EP4554581A1 (en) 2022-07-13 2025-05-21 Monte Rosa Therapeutics AG Combination therapy comprising gspt1-directed molecular glue degraders and pi3k/akt/mtor pathway inhibitors
US20260014133A1 (en) * 2022-07-15 2026-01-15 St. Jude's Chidren's Research Hospital, Inc. SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物
WO2024073871A1 (en) * 2022-10-04 2024-04-11 Biofront Ltd Gspt1 degraders, compositions comprising the degrader, and methods of using the same
CN117917402A (zh) * 2022-10-21 2024-04-23 暨南大学 异吲哚酰胺类化合物及其药物组合物和应用
WO2024109918A1 (zh) * 2022-11-24 2024-05-30 西藏海思科制药有限公司 一种gspt1降解剂及其在医药上的应用
KR102570883B1 (ko) * 2023-04-13 2023-08-29 (주) 사이러스테라퓨틱스 신규한 gspt1 분해제 및 이의 용도
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
WO2025067255A1 (zh) * 2023-09-26 2025-04-03 映恩生物制药（苏州）有限公司 哌啶二酮类化合物、其制备方法和用途
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507342A (ja) 1996-12-17 2001-06-05 ワーナー−ランバート・コンパニー 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023617A1 (en) 1996-11-26 1998-06-04 American Cyanamid Company Hetero-biaryl-pyridoquinazolinone derivatives as anti-cancer agents
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
PL371344A1 (en) * 2002-02-13 2005-06-13 Glaxo Group Limited Benzenesulfonamide derivatives as antipsychotic agents
CA2822094C (en) 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CN101578277A (zh) * 2006-08-30 2009-11-11 细胞基因公司 5-取代的异二氢吲哚化合物
AU2007290407A1 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
US7938952B2 (en) 2008-05-20 2011-05-10 Institute Francais Du Petrole Process for multistage residue hydroconversion integrated with straight-run and conversion gasoils hydroconversion steps
CA2957226C (en) 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
JP5944823B2 (ja) 2010-07-02 2016-07-05 あすか製薬株式会社 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤
UA116544C2 (uk) 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CA2908954C (en) 2013-04-17 2021-08-03 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
AU2016266942B2 (en) * 2015-05-22 2018-10-18 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
EP3399980B1 (en) * 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
TWI782395B (zh) 2016-01-08 2022-11-01 美商西建公司 抗增生化合物，及其醫藥組合物及用途
SG11201809501PA (en) * 2016-06-06 2018-12-28 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP4119552A1 (en) 2017-02-08 2023-01-18 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
CN108929307A (zh) 2017-05-22 2018-12-04 苏州偶领生物医药有限公司 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途
JP2019017801A (ja) 2017-07-19 2019-02-07 株式会社島津製作所 Ｘ線撮影装置
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
KR102129367B1 (ko) * 2017-10-20 2020-07-03 한국화학연구원 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
CN118344338A (zh) 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
US12030892B2 (en) 2018-06-29 2024-07-09 Dana-Farber Cancer Institute, Inc. CRBN modulators
EP3820532A4 (en) 2018-07-11 2022-04-06 H. Lee Moffitt Cancer Center & Research Institute, Inc. DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS
WO2020118098A1 (en) * 2018-12-05 2020-06-11 Vividion Therapeutics, Inc. Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
US20240124459A9 (en) 2020-06-29 2024-04-18 Dana-Farber Cancer Institute, Inc. Prpk inhibitors
IL301564A (en) 2020-09-23 2023-05-01 Transposon Therapeutics Inc LINE-1 inhibitors to treat the disease
MX2023003362A (es) 2020-09-23 2023-05-30 Scorpion Therapeutics Inc Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001507342A (ja) 1996-12-17 2001-06-05 ワーナー−ランバート・コンパニー 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & medicinal chemistry letters. Vol.27, No.17*

Also Published As

Publication number Publication date
JP2023542930A (ja) 2023-10-12
AU2021347238A1 (en) 2023-06-01
IL301588A (en) 2023-05-01
EP4217352A1 (en) 2023-08-02
KR20220080003A (ko) 2022-06-14
MX2023003114A (es) 2023-03-23
BR112023005344A2 (pt) 2023-05-09
US20240132463A1 (en) 2024-04-25
ZA202304644B (en) 2025-11-26
JP7856636B2 (ja) 2026-05-11
US12454518B2 (en) 2025-10-28
CN116209439B (zh) 2026-05-26
PE20230847A1 (es) 2023-05-23
US12454519B2 (en) 2025-10-28
EP4217352A4 (en) 2024-04-10
CN116209439A (zh) 2023-06-02
WO2022066835A1 (en) 2022-03-31
US20220274948A1 (en) 2022-09-01
CL2023000394A1 (es) 2023-08-18
CA3196278A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
JP7856636B2 (ja) セレブロンタンパク質のモジュレータとしての置換ｎ－（２－（２，６－ジオキソピペリジン－３－イル）－１，３－ジオキソイソインドリン－５－イル）アリールスルホンアミド類似体
CN115666563A (zh) 作为kras抑制剂的取代的7-(哌嗪-1-基)吡唑并[1,5-a]嘧啶类似物的组合物和方法
JP2023120446A (ja) アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用
IL263752A (en) Training modulating compounds
KR102765922B1 (ko) 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
JP2020527577A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
KR102655595B1 (ko) 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도
CA2922753A1 (en) 1-(4-pyrimidinyl)-1h-pyrrolo[3,2-c]pyridine derivatives as nik inhibitors
US20260014133A1 (en) SUBSTITUTED 3-(l-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE/2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-l,3-DIONE ANALOGS AS MODULATORS OF CEREBLON PROTEIN
WO2023205807A2 (en) Proteolysis targeting chimeras for human pregnane x receptor and for degradation of gspt1
US20250034107A1 (en) Substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-5-yl) acetamide analogs as modulators of gspt1 and/or ikzf1 protein
EP3645006A1 (en) Heterochromatin gene repression inhibitors
RU2853173C1 (ru) Замещенные аналоги n-(2-(2,6-диоксопиперидин-3-ил)-1,3-диоксоизоиндолин-5-ил)арилсульфонамида в качестве модуляторов белка цереблона
HK40087102A (en) Modulators of cereblon protein
US20250122166A1 (en) Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)methyl)benzamide analogs as modulators of cereblon protein
CN115361948A (zh) 抑制二氢乳清酸脱氢酶的方法和组合物
US20250129045A1 (en) Small molecule pim and mtor kinase inhibitor and methods of use thereof
WO2025155827A1 (en) Small-molecule modulators of lymphocyte-specific protein tyrosine kinase and casein kinase 1a
WO2025240852A1 (en) Therapeutic compositions and methods thereof

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4